Analyst recommendations: Abercrombie & Fitch, Eli Lilly, Philip Morris, Ulta
Analysts updated recommendations for several companies. Baptista Research raised Abercrombie & Fitch's price target to $163.40 but downgraded it to hold. Eli Lilly was upgraded to buy by Berenberg, which also raised its target to $1,400. Other companies affected include Coinbase, Ulta Beauty, and Philip Morris.
How this was made
The 30-second read
Why it matters
Aggregated rating changes provide a snapshot of analyst sentiment but lack a single decisive catalyst.
Market read
The collection of rating adjustments may influence short-term trading decisions across the listed stocks.
What to watch
Potential macro headwinds could dampen the impact of individual upgrades.
Background
Morning analyst recommendation roundup covering multiple U.S. stocks.
Ticker impact
Baptista Research downgrades Abercrombie & Fitch to hold and raises price target.
Modest decline expected.
Downgrade signals weaker outlook despite higher target.
JP Morgan downgrades Aptiv to neutral and cuts price target.
Slight pullback anticipated.
Neutral rating reduces growth expectations.
Zacks maintains neutral on Coinbase but raises price target dramatically.
Limited upside potential.
Target increase is large but rating unchanged.
Berenberg upgrades Eli Lilly to buy and raises price target.
Potential modest rally.
Buy rating reflects stronger outlook.
Oppenheimer upgrades Etsy to outperform with a $90 target.
Small upside expected.
Outperform rating signals confidence.
JP Morgan downgrades Lear to neutral and cuts price target.
Modest decline likely.
Neutral stance reduces growth expectations.
William O'Neil upgrades Philip Morris to buy after coverage suspension.
Potential modest gain.
Buy rating indicates improved outlook.
RBC upgrades Resmed to outperform and raises price target.
Small upside expected.
Outperform rating signals confidence.
Market effects
Broad analyst rating changes may slightly shift consumer discretionary sentiment.
U.S. equities may see modest volatility across retail and tech sectors.
Limited to U.S. listed companies; minimal global effect.
Counterpoint
Rating upgrades may be premature given broader market weakness.
Key entities
- AnalystBaptista Research
Downgraded Abercrombie & Fitch.
- AnalystJP Morgan
Provided several downgrades and upgrades.
